Tag: Cirmtuzumab
Zilovertamab vedotin Demonstrates Encouraging Clinical Activity in B-Cell Cancers
A novel ROR1-targeted antibody-drug conjugate (ADC), zilovertamab vedotin, also known as MK-2140 or VLS-101, has demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable...
Merck Acquires VelosBio and Strengthens Oncology Pipeline with Investigational Antibody-Drug Conjugates
Merck & Co (MSD) has agreed to acquire VelosBio, a privately held clinical-stage biopharmaceutical company, for U.S. $ 2.75 billion in cash, subject to...
Oncternal Therapeutics Announces Closing of an $18.4 million Series B Financing.
Clinical-stage biotechnology company Oncternal Therapeutics announced the closing of an $18.4 million Series B financing. The company which develops first-in-class and novel therapies for...
